Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.

	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue		345K -	1.01M 192.75%	399K 60.50%
gross profit		-345K -	-1.01M 192.75%	-399K 60.50%
selling and marketing expenses	1.77M -			-399K -
general and administrative expenses	3.55K -	10.08M 283,495.95%	21.44M 112.72%	27.93M 30.28%
selling general and administrative expenses	1.78M -	10.08M 467.19%	21.44M 112.72%	27.53M 28.42%
research and development expenses	4.51M -	32.33M 616.22%	47.44M 46.75%	60.93M 28.43%
other expenses		-877K -	-44K 94.98%
cost and expenses	6.29M -	42.41M 574.12%	68.88M 62.43%	88.87M 29.01%
operating expenses	6.29M -	42.41M 574.12%	68.88M 62.43%	88.47M 28.43%
interest expense			-78.00K -
ebitda	-6.29M -	-42.41M 574.12%	-68.88M 62.43%	-88.47M 28.43%
operating income	-6.29M -	-42.41M 574.12%	-68.88M 62.43%	-88.87M 29.01%
depreciation and amortization	12.58K -	28K 122.54%	78K 178.57%	399K 411.54%
total other income expenses net	-22.25M -	-874K 96.07%	579K 166.25%	6.23M 975.65%
income before tax	-28.55M -	-43.28M 51.63%	-68.31M 57.81%	-82.64M 20.98%
income tax expense	-12.58K -	-31K 146.38%	-579.00K 1,767.74%
net income	-28.55M -	-43.25M 51.52%	-67.73M 56.58%	-82.64M 22.02%
weighted average shs out	28.26M -	1.53M 94.58%	31.69M 1,968.64%	38.71M 22.18%
weighted average shs out dil	28.26M -	1.53M 94.58%	31.69M 1,968.64%	38.71M 22.18%
eps	-1.01 -	-28.24 2,696.04%	-2.14 92.42%	-2.13 0.47%
epsdiluted	-1.01 -	-28.24 2,696.04%	-2.14 92.42%	-2.13 0.47%

NASDAQ:VIGL

Vigil Neuroscience, Inc.

Last Close

3.57

08/11 21:00

Market Cap

157.48M

Beta: -

Volume Today

47.57K

Avg: 22.58K

PE Ratio

−2.36

PFCF: −1.35

Preview